DM Intelligence Completes Nearly RMB 10 Million Angel Funding Round to Advance AI-Driven Drug Discovery Toward Clinical Translation

On April 19, 2021, Guangzhou DM Intelligence Ltd. (DM Intelligence, hereinafter referred to as “DM Intelligence”), an R&D collaboration-oriented AI-driven new drug development company, announced the completion of its angel financing round amounting to nearly RMB 10 million (specific amount undisclosed). The angel round was led by Guangzhou Nanshan Venture Capital Fund Partnership Enterprise (Limited Partnership). Following this round of financing, DM Intelligence will continue to enhance the construction of its core platform (the AI-based new drug creation platform) and accelerate the preclinical advancement of its AI-driven drug candidates in the pipeline.

Dr. Xie Weidong, Chairman and General Manager of DM Intelligence“DM Intelligence’s team boasts over 30 years of experience in drug R&D, with profound insights into the selection of indications, pathogenic mechanisms, targets, and drug types. By integrating artificial intelligence technology, the company has accelerated its AI-driven new drug development, establishing multi-dimensional comprehensive algorithmic models that significantly enhance screening efficiency. This approach enables the identification of novel and diverse active compounds, alongside a global patent layout. Currently, the company focuses on small-molecule targeted drug pipelines in the fields of oncology, neurodegeneration, infection, and autoimmune diseases, prioritizing validated targets with urgent market needs. The company’s AI-powered new drug creation platform has demonstrated remarkable potential. We are capable of obtaining experimentally validated, structurally novel and diverse hit compounds that break through patent barriers within three months. After more than two years of development, the company has established over 10 internal pipelines and five external collaborative pipelines. Among these, the Parkinson’s disease pipeline is progressing rapidly, showing superior experimental results compared to similar drugs under development. DM Intelligence will continue to prioritize these pipelines to further drive corporate growth. The DM Intelligence AI new drug creation platform integrates multidisciplinary expertise from medicinal chemistry, biology, mathematics, and bioinformatics. Its multi-dimensional comprehensive algorithmic models achieve screening efficiency far exceeding traditional methods, and various novel structural compounds identified through AI screening have already secured global patent protection.”

Chen Weiyu, Fund Manager of Guangzhou Nanshan Venture Capital Fund Partnership Enterprise (Limited Partnership)He stated, “There is no doubt that AI has enhanced production efficiency across various industries and will also significantly accelerate the discovery of new drugs, improve their quality, and reduce R&D costs. AI-driven drug development requires not only powerful computational capabilities but also extensive experience in new drug R&D to construct algorithmic models. Dr. Xie, founder of DM Intelligence, graduated from Imperial College London. With over 30 years of experience in pharmaceutical R&D and new drug assessment at academic research institutions, renowned domestic and international pharmaceutical companies, and overseas healthcare investment firms, he possesses profound analytical expertise in the selection and valuation of innovative drug targets.”

These experiences and capabilities have a critical impact on enhancing the efficiency and success rate of AI-driven new drug discovery and development at DM Intelligence, as evidenced by the company’s remarkable achievements over a relatively short period.

DM Intelligence’s pipeline of lead compounds targeting novel indications such as oncology and neurodegenerative diseases is expected to demonstrate high market potential in terms of efficacy, pharmacokinetics, and other investigational parameters.

DM Intelligence, with a global perspective, focuses on clinical needs and drug value, dedicated to differentiated R&D of innovative drugs to benefit patients worldwide.

Leveraging massive and diverse databases, integrating optimized machine learning and deep learning algorithms with intelligent Computer-Aided Drug Design (CADD) as its core, and utilizing high-performance computing as an accelerator, the company has established an AI-driven new drug discovery platform. This platform focuses on predicting drug activity and ADMET properties, analyzing drug-target interactions, and generating small molecules, with the aim of accelerating hit and lead identification as well as Preclinical Candidate (PCC) optimization, thereby establishing competitive advantages in the speed, precision, and scope of innovative drug R&D.

In addition to independently developing its own diverse pipeline, the company employs various business models—including lead optimization and preclinical candidate (PCC) co-development—to empower innovative pharmaceutical enterprises in accelerating the R&D of best-in-class and first-in-class drugs. It has currently established collaborations with several renowned pharmaceutical companies, such as Medicilon and Dabo Bio.

The Guangzhou Nanshan Venture Capital Fund is a technology transfer investment fund established through the collaboration of Academician Zhong Nanshan of the Chinese Academy of Engineering as the leading figure, the Guangdong Nanshan Institute of Pharmaceutical Innovation as the lead institution, Nast Investment Management Co., Ltd. as the fund manager, Degaoxin Holding Group Co., Ltd. as the cornerstone investor, and the Greater Bay Area Science and Technology Innovation Service Center as the policy and investment advisor. The fund primarily invests in scientific research institutions, new-type R&D institutions, and university technology transfer projects in the fields of biopharmaceuticals and related industries. Focusing on the advantageous technological domains of universities and research institutions in Guangzhou, the fund aims to integrate the technology transfer system with the venture capital matchmaking system through a “enterprise + technology + capital” model, achieving “precise matchmaking” between the supply and demand sides of scientific and technological achievements, promoting efficient transfer and commercialization of these achievements, and fostering deep integration among industry, academia, and research.